AbbVie Inc.

ABBV

US00287Y1091

Pharmaceuticals

Market Closed - Nyse Other stock markets 21:00:03 13/02/2026 GMT			5-day change	1st Jan Change
231.50 ^USD	+1.76%		+3.61%	+1.32%

02-13	China Medical University Hospital Collaborates with Ever Supreme Bio Technology to Develop Exosome Platform	CI
02-12	AbbVie sues US health agency over Botox price controls	RE

AbbVie Enters Cancer Treatment Space via RemeGen Licensing Deal, UBS Says

Published on 01/13/2026 at 08:07 pm GMT

MT Newswires

Latest news about AbbVie Inc.

02-13	China Medical University Hospital Collaborates with Ever Supreme Bio Technology to Develop Exosome Platform	CI
02-12	AbbVie sues US health agency over Botox price controls	RE
02-12	West Pharma forecasts 2026 profit above estimates on strong demand for drug components	RE
02-12	West Pharmaceutical Services, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2026	CI
02-11	AbbVie sues US health agency over Botox	RE
02-11	AbbVie sues U.S. Department of Health and Human Services over selection of Botox for IRA Medicare drug negotiations	RE
02-09	BNP Paribas Exane Adjusts Price Target on AbbVie to $213 From $203, Maintains Neutral Rating	MT
02-05	Evercore ISI Adjusts Price Target on AbbVie to $228 From $232, Maintains Outperform Rating	MT
02-05	Goldman Sachs Adjusts Price Target on AbbVie to $240 From $223, Maintains Neutral Rating	MT
02-05	Morgan Stanley Lifts Price Target on AbbVie to $270 From $269, Keeps Overweight Rating	MT
02-04	Health Care Up After Eli Lilly Earnings -- Health Care Roundup	DJ
02-04	Nasdaq, S&P 500 Fall as Tech Sell-Off Continues	MT
02-04	Evercore ISI Adjusts AbbVie Price Target to $228 From $232, Maintains Outperform Rating	MT
02-04	Sector Update: Health Care Stocks Rise Wednesday Afternoon	MT
02-04	AbbVie Inc., Q4 2025 Earnings Call, Feb 04, 2026

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.4%), Germany (2.6%), Japan (2%), Canada (1.9%), China (1.6%), France (1.4%), Spain (1%), the United Kingdom (0.9%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and other (9.7%).

Employees

55,000

Sector

Pharmaceuticals

Calendar

04-23 - Q1 2026 Earnings Release (Projected)

More about the company